Selegiline delays the onset of disability in de novo parkinsonian patients

Neurology

Volumn 51, Issue 2, 1998, Pages 520-525

  Pålhagen, Sven ^a   Heinonen, E H ^b   Hagglund J ^c   Kaugesaar, T ^d   Kontants, H ^f   Maki Ikola O ^b   Palm, R ^e   Turunen, J ^b  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b ORION CORPORATION   (Finland)

^c Malar Hospital   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e CENTRAL HOSPITAL   (Sweden)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DOUBLE BLIND PROCEDURE; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; XEROSTOMIA;

EID: 0345019854     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.2.520     Document Type: Article

References (25)

1. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
2. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
3. Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992;42:339-343.
4. Tetrud J, Langsten W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245: 519-522.
5. Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease. Acta Neurol Scand 1995;91:177-182.
6. Larsen JP, Boas J, the Norwegian-Danish Parkinson Study Group. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability. An interim analysis of a Norwegian-Danish 5 year study. Mov Disord 1997;12:175-182.
7. Przuntek H, Conrad B, Dichgans J, et al. Five years analysis of the seledo study. In: 11th International Symposium on Parkinson's Disease. Rome, 1994:250. Abstract.
8. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
9. Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH. Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurol Scand 1997;95:211-218.
10. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of neurologic deficit. Boston: Butterworths, 1989:285-309.
11. Schwab RS, England AC. In: Gillingham FJ, Donaldson MC, eds. Third symposium on Parkinson's disease. Edinburgh: Livingstone, 1969:152-157.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
13. Ganz PA. Methods of assessing the effect of drug therapy on quality of life. Drug Saf 1990;5:233-242.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Hamilton MA. Rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
16. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO-B after L-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93.
17. 11C]deprenyl. Neurology 1996;46: A453. Abstract.
18. Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245.
19. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
20. Mäki-Ikola O, Heinonen EH. Study design problems of DATATOP study analysis. Ann Neurol 1996;40:946-947.
21. Penney JB, Shoulson I, Kieburtz K, Oakes D. Study design problems of DATATOP study analysis: reply. Ann Neurol 1996;40:947-948.
22. Salonen T, Haapalinna A, Heinonen E, Suhonen J, Hervonen A. Monoamine oxidase B inhibitor selegiline protects young and aged rats peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol 1996;91:466-474.
23. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(suppl 3):171-183.
24. Brannan T, Yahr M. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-98.
25. Lees A on behalf of the Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.